News
Long-term results of alpha-1-antitrypsin deficiency treatment – RAPID program
RAPID/RAPID Extension is the largest clinical program to date that has confirmed the benefit of alpha-1-antitrypsin inhibitor in the treatment of chronic obstructive pulmonary disease (COPD) associated with its deficiency.
How Common is Alpha-1 Antitrypsin Deficiency?
What is the prevalence of alpha-1 antitrypsin deficiency (AATD)? What comorbidities are associated…
Did the Extension of the TOWER Study Confirm the Position of Teriflunomide?
The results of the TOWER study extension were published this August in the prestigious journal…
Perioperative Management of Bleeding in Patients with von Willebrand Disease Using Coagulation Factors
Von Willebrand disease is one of the most common congenital bleeding disorders. It is a…
DPP4 Inhibitors in Chronic Kidney Disease and Their Potential to Protect Against Diabetic Nephropathy
Preclinical and clinical observations suggest that dipeptidyl peptidase 4 (DPP4) inhibitors might offer...
Is It Necessary to Discontinue Dupilumab in Patients with Atopic Dermatitis During the COVID-19 Pandemic?
Italian authors described their experiences with remote treatment of 200 atopic dermatitis (AD)…
The safety of dupilumab allows treatment of atopic dermatitis without routine laboratory monitoring
The first comprehensive analysis of laboratory data from 3 clinical trials with dupilumab assessed…
Efficacy of Bruton Tyrosine Kinase Inhibitors After Venetoclax Therapy in Patients with CLL
Targeted therapy has changed the treatment approach for chronic lymphocytic leukemia (CLL), showing…
When to Switch to Second-Line Treatment for Primary Biliary Cholangitis?
In patients with primary biliary cholangitis (PBC), the response to ursodeoxycholic acid (UDCA)…
Frequent Nausea During Chemotherapy Despite Antiemetic Prophylaxis
Current clinical research has focused on vomiting as a primary issue in the occurrence of CINV…